口服甲泼尼龙对IgA肾病患者临床结局的影响:TESTING随机临床试验
TESTING多中心双盲随机试验计划纳入750例IgA肾病患者,因严重不良事件过多在262例入组后提前终止。中位随访2.1年,甲泼尼龙组严重事件14.7% vs 安慰剂组3.2%(P=.001),主要肾脏结局5.9% vs 15.9%(HR 0.37,95%CI 0.17-0.85;P=.02)。
要点
- 甲泼尼龙组严重不良事件14.7% vs 安慰剂组3.2%,主要为严重感染(8.1% vs 0),包括2例死亡。
- 主要肾脏复合结局甲泼尼龙组5.9% vs 安慰剂组15.9%(HR 0.37,95%CI 0.17-0.85;P=.02)。
- 因严重不良事件过多试验提前终止,无法对治疗获益作出确定性结论。
核心结论
- 在蛋白尿≥1 g/d的IgA肾病患者中,口服甲泼尼龙与严重不良事件风险增加相关,主要为感染。
- 结果与潜在肾脏获益一致,但因试验提前终止,无法对治疗获益作出确定性结论。
研究设计与样本
- TESTING研究为多中心、双盲、随机临床试验,计划招募750例IgA肾病患者。
- 入组条件为经至少3个月肾素-血管紧张素系统阻断剂控制血压后,蛋白尿大于1 g/d且eGFR 20-120 mL/min/1.73 m²,随访至发生335例主要结局。
- 实际随机262例(平均年龄38.6岁[SD 11.1];女性96例[37%];eGFR 59.4 mL/min/1.73 m²;尿蛋白排泄2.40 g/d),中位随访2.1年后因严重不良事件过多终止招募。
- 患者按1:1随机接受口服甲泼尼龙(0.6-0.8 mg/kg/d;最大48 mg/d)(n=136)或匹配安慰剂(n=126)治疗2个月,随后4至6个月逐渐减量。
主要发现
- 严重事件发生于甲泼尼龙组20例(14.7%)vs 安慰剂组4例(3.2%)(P=.001;风险差11.5%[95%CI 4.8%-18.2%])。
- 严重感染发生于甲泼尼龙组11例(8.1%)vs 安慰剂组0例(风险差8.1%[95%CI 3.5%-13.9%];P<.001),包括2例死亡。
- 主要肾脏结局(终末期肾病、肾衰竭死亡或eGFR下降40%)发生于甲泼尼龙组8例(5.9%)vs 安慰剂组20例(15.9%)(HR 0.37[95%CI 0.17-0.85];风险差10.0%[95%CI 2.5%-17.9%];P=.02)。
关键数值与推荐
- 预设安全性结局为严重感染、新发糖尿病、胃肠道出血、骨折/骨坏死和心血管事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 因严重不良事件过多,招募提前终止。
- 中位随访2.1年,未达到预估的平均5年随访。
- 因试验提前终止,无法对治疗获益作出确定性结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Guidelines recommend corticosteroids in patients with IgA nephropathy and persistent proteinuria, but the effects remain uncertain. OBJECTIVE: To evaluate the efficacy and safety of corticosteroids in patients with IgA nephropathy at risk of progression. DESIGN, SETTING, AND PARTICIPANTS: The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study was a multicenter, double-blind, randomized clinical trial designed to recruit 750 participants with IgA nephropathy (proteinuria greater than 1 g/d and estimated glomerular filtration rate [eGFR] of 20 to 120 mL/min/1.73 m2 after at least 3 months of blood pressure control with renin-angiotensin system blockade] and to provide follow-up until 335 primary outcomes occurred. INTERVENTIONS: Patients were randomized 1:1 to oral methylprednisolone (0.6-0.8 mg/kg/d; maximum, 48 mg/d) (n = 136) or matching placebo (n = 126) for 2 months, with subsequent weaning over 4 to 6 months. MAIN OUTCOMES AND MEASURES: The primary composite outcome was end-stage kidney disease, death due to kidney failure, or a 40% decrease in eGFR. Predefined safety outcomes were serious infection, new diabetes, gastrointestinal hemorrhage, fracture/osteonecrosis, and cardiovascular events. The mean required follow-up was estimated to be 5 years. RESULTS: After randomization of 262 participants (mean age, 38.6 [SD, 11.1] years; 96 [37%] women; eGFR, 59.4 mL/min/1.73 m2; urine protein excretion, 2.40 g/d) and 2.1 years' median follow-up, recruitment was discontinued because of excess serious adverse events. Serious events occurred in 20 participants (14.7%) in the methylprednisolone group vs 4 (3.2%) in the placebo group (P = .001; risk difference, 11.5% [95% CI, 4.8%-18.2%]), mostly due to excess serious infections (11 [8.1%] vs 0; risk difference, 8.1% [95% CI, 3.5%-13.9%]; P < .001), including 2 deaths. The primary renal outcome occurred in 8 participants (5.9%) in the methylprednisolone group vs 20 (15.9%) in the placebo group (hazard ratio, 0.37 [95% CI, 0.17-0.85]; risk difference, 10.0% [95% CI, 2.5%-17.9%]; P = .02). CONCLUSIONS AND RELEVANCE: Among patients with IgA nephropathy and proteinuria of 1 g/d or greater, oral methylprednisolone was associated with an increased risk of serious adverse events, primarily infections. Although the results were consistent with potential renal benefit, definitive conclusions about treatment benefit cannot be made, owing to early termination of the trial. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01560052.
引用
- Lv J, Zhang H, Wong MG, et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2017. PMID: 28763548. doi:10.1001/jama.2017.9362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。